Rhode Island is getting about $1.2 million to settle claims that British drug maker GlaxoSmithKline LLC deceptively promoted the diabetes drug Avandia.
The payment is part of a $90 million settlement between GlaxoSmithKline and attorneys general from 38 different states.
Attorney General Peter Kilmartin and colleagues claim the company misrepresented Avandia's cardiovascular risks and safety profile. The agreement requires the company to reform its marketing practices and to publicize information about any company-sponsored clinical trials on its diabetes drugs.
GlaxoSmithKline doesn't admit any wrongdoing. A spokeswoman says the company firmly believes it acted responsibly in testing, marketing and monitoring the safety of Avandia. Associated Press